Table 2.
Clinical, morphological, biochemical, and haematological characteristics in normal controls and patients with chronic pancreatitis or Sjögren’s syndrome
| Controls | ICP | Alcoholic CP | Sjögren’s syndrome | |
| Attacks of pancreatitis | 0 (0/54) | 33.3 (18/54)** | 81.4 (70/86)**†† | 0 (0/33)†† |
| Abdominal pain | 0 (0/54) | 60.4 (32/54)** | 91.9 (79/86)**†† | 9.1 (3/33)*†† |
| Cholestasis/jaundice | 0 (0/54) | 22.2 (12/54)** | 27.9 (24/86)** | 0 (0/33)†† |
| Associated autoimmune disorders | 0 (0/54) | 35.2 (19/54)** | 22.1 (19/86)** | 69.7 (23/33)**†† |
| Pancreatic mass | 0 (0/54) | 24.1 (13/54)** | 2.4 (2/86)**† | 0 (0/33)†† |
| Calcifications | 0 (0/54) | 44.4 (24/54)** | 82.6 (71/86)**†† | 0 (0/33)†† |
| Pseudocysts | 0 (0/54) | 16.7 (9/54)** | 49.4 (42/85)**†† | 0 (0/33)† |
| Eosinophilia | 5.6 (3/54) | 13.0 (7/54) | 12.8 (11/86) | 0 (0/33)† |
| ANA | 7.4 (4/54) | 13 (7/54) | 10.5 (9/86) | 51.5 (17/33)**†† |
| Antimitochondrial Ab | 0 (0/54) | 3.7 (2/54) | 1.2 (1/86) | 6.1 (2/33) |
| Antismooth muscle Ab | 1.9 (1/54) | 5.6 (3/54) | 7.1 (6/85) | 3 (1/33) |
| SS-B | 0 (0/54) | 1.9 (1/54) | 1.2 (1/86) | 39.4 (13/33)**†† |
Results are expressed as percentage (number of positive cases/total number of cases).
CP, chronic pancreatitis; ICP, idiopathic chronic pancreatitis; ANA, antinuclear antibodies; Ab, antibodies; Eosinophilia, >350×109 eosinophils/l.
*p<0.05, **p<0.01 versus controls; †p<0.05, ††p<0.01 versus ICP.